Derecho de Sucesiones

La muerte de una persona es uno de los hechos jurídicos que mayor trascendencia acarre dentro del ordenamiento jurídico, no solo por implica el fin de la existencia de la persona, sino por todas aquellas consecuencia de índole patrimonial que ocasiona; por esta razón, su inclusión se convierte en un imperativo categórico para la buena formación del estudiantado. La prolongación de la personalidad jurídica del difunto en sus herederos es una de la ficciones legales de mayor importancia, de forma que constituye el mecanismo por medio del cual la ciencia jurídica ha configurado la transmisión de tanto de los derechos como de las obligaciones del de cuius, así se proporciona una efectiva seguridad jurídica concretada en el hecho de que, salvo en el caso de los derechos y obligaciones personalísimos, todas, las relaciones patrimoniales de la persona no extinguen por el hecho de su fallecimiento. Para comprender la trascendencia y significancia del Derecho sucesorio y de sus instituciones es insoslayable estudiar sus orígenes en Derecho romano, así como su evolución histórica; de esta manera, el estudiantado tendrá una visión integral de la materia objeto de nuestro estudio

Disease activity score (DAS) response/remission after 3–6 months therapy with etanercept with or without methotrexate (MTX)

<p><b>Copyright information:</b></p><p>Taken from "Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious"</p><p>Arthritis Research & Therapy 2003;5(6):R347-R351.</p><p>Published online 1 Oct 2003</p><p>PMCID:PMC333416.</p><p>Copyright © 2003 van Vollenhoven et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</p> Data are the percentages of patients achieving the European League Against Rheumatism criteria for moderate/good clinical response and for remission

Additional file 1: Table S1. of IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis

Demographic characteristics of the nationwide EIRA cohort. Table S2. Characterized complement pathway proteins and IgG-isotype proteins. Table S3. Individual IgG-Fc glycan distribution values in IgG1 and in IgG2 in control subjects, as well as in patients with RA prior to and following MTX treatment. Table S4. Significant differences for the 19 characterized glycan species when comparing healthy versus all, good, moderate, and nonresponding patients prior to and following MTX treatment. Table S5. IgG1 and IgG2 Fc glycan distributions grouped according to structural features, comparing healthy control subjects and patients with RA prior to and following MTX treatment. Table S6. Intra- and interindividual differences in the patients with RA, comparing individual glycan species prior to and following MTX treatment. Table S7. Complete list, ranking, and correlation (with response versus no response to MTX) of the features used in the OPLS-DA model shown in Fig. 3b. Figure S1. Extracted ion chromatograms of IgG1 and IgG2 Fc glycans quantified in a control subject and a patient with RA. Figure S2. Intraindividual changes in galactosylation status on IgG1 and on IgG2 for good and moderate responders and for nonresponders. Figure S3. Intraindividual correlation between the aGal/Gal status of glycans with different types of structural features and of IgG1 and IgG2 substituted glycans. Figure S4. Significant differences between control subjects and patients with early RA at baseline in the classical pathway initiating complements C1 and C9. Figure S5. Intraindividual correlation between the classical and lectin pathway inhibitor C4bBPα versus FA2/(FA2G1 + FA2G2). (DOCX 1180 kb

Association between <i>NPSR1</i> SNPs and rheumatoid arthritis in ACPA-negative patients vs controls.

#<p>Minor allele in lower case.</p>§<p>MAF  =  minor allele frequency.</p><p>°Minor allele is the tested allele.</p><p>*significant after Bonferroni correction for multiple testing.</p

LD map and characteristics of the studied <i>NPSR1</i> SNPs.

<p>Left: LD and haplotype block structure obtained by Haploview 4 analysis of genotyping data from the EIRA population. The numbers in each box correspond to R-square values between SNPs. Right: SNPs are listed based on their relative distance in bp and their position in both the <i>NPSR1</i> gene and its corresponding mRNA).</p

Frequency of GSTM1 CNV and severity of RA.

<p>DAS28 and Larsen score retrieved at baseline.</p><p>Non-parametric statistical test (Mann-Whitney).</p

Presence of GSTM1 and risk of developing ACPA-positive and ACPA-negative RA in relation to gender and age.

<p>Ca/Co = Cases and controls.</p><p>OR = odds ratio.</p><p>95% CI = 95% confidence interval.</p

Frequency of GSTM1 CNV in EIRA by ACPA status and different subgroups according to smoking and <i>HLA</i>-DRB1 status.

<p>Ca/Co = Cases and controls.</p><p>OR = odds ratio.</p><p>95% CI = 95% confidence interval.</p

Association between <i>NPSR1</i> SNPs and DAS28 in rheumatoid arthritis patients.

#<p>Minor allele in lower case.</p>§<p>A  =  major allele: a  =  minor allele.</p><p>°Minor allele is the tested allele.</p><p>*significant after Bonferroni correction for multiple testing.</p

Influence of GSTM1 on development of ACPA-positive RA in relation to SE and smoking.

<p>Ca/Co = Cases and controls.</p><p>OR = odds ratio.</p><p>95% CI = 95% confidence interval.</p